Health Economics›Breast cancer›Metastatic disease first-line therapy

Metastatic disease first-line therapy

Breast cancer · 49 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

FiltersBiomarker

Y-axis

Cost vs Efficacy · 40 points

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
nab-Paclitaxel and Pembrolizumab Variant #01	TNBC	R 130 117	28d	7.8 mo	23.0 mo	2	R 260 234 PFS proxy	2
nab-Paclitaxel and Atezolizumab Variant #01	TNBC	R 91 886	28d	—	21.0 mo	2	R 183 773 PFS proxy	1
Carboplatin and Gemcitabine (GCb) and Pembrolizumab Variant #01	TNBC	R 86 402	21d	7.8 mo	23.0 mo	35	R 3 024 057 PFS proxy	2
Paclitaxel and Pembrolizumab Variant #01	TNBC	R 84 190	28d	7.8 mo	23.0 mo	2	R 168 381 PFS proxy	2
nab-Paclitaxel and Toripalimab Variant #01 Partial	TNBC	R 40 108	21d	8.4 mo	32.8 mo	35	R 1 403 786 PFS proxy	2
Vinorelbine and Trastuzumab (VH) Variant #01	ER\|ERBB2	R 39 320	28d	14.8 mo	—	3	R 61 725 PFS proxy	1
Lapatinib and Letrozole Variant #01	ER\|ERBB2	R 38 048	28d	8.2 mo	—	2	R 76 096 PFS proxy	1
Fulvestrant and Ribociclib Variant #01	ER	R 37 135	28d	20.5 mo	60.7 mo	3	R 84 197 PFS proxy	3
Exemestane, Lapatinib, Trastuzumab Variant #01	ER\|ERBB2	R 33 561	21d	11.0 mo	—	3	R 77 253 PFS proxy	1
Lapatinib, Letrozole, Trastuzumab Variant #01	ER\|ERBB2	R 33 175	21d	11.0 mo	—	3	R 76 095 PFS proxy	1
Anastrozole, Lapatinib, Trastuzumab Variant #01	ER\|ERBB2	R 33 017	21d	11.0 mo	—	3	R 75 618 PFS proxy	1
Letrozole and Bevacizumab Variant #01	ER	R 30 264	21d	19.8 mo	—	2	R 60 529 PFS proxy	2
Docetaxel and Trastuzumab (TH) Variant #02	ER\|ERBB2	R 19 252	21d	12.5 mo	40.8 mo	3	R 34 468 PFS proxy	9
Abemaciclib and Letrozole Variant #01	ER	R 16 291	28d	28.2 mo	66.8 mo	2	R 32 581 PFS proxy	3
Abemaciclib and Anastrozole Variant #01	ER	R 16 079	28d	28.2 mo	66.8 mo	2	R 32 158 PFS proxy	3
nab-Paclitaxel monotherapy Variant #01	TNBC	R 16 043	28d	6.9 mo	18.7 mo	2	R 32 087 PFS proxy	5
Paclitaxel and Trastuzumab (TH) Variant #01	ER\|ERBB2	R 15 366	21d	13.7 mo	24.0 mo	4	R 28 660 PFS proxy	8
Capecitabine and Trastuzumab (XH) Variant #01	ER\|ERBB2	R 15 097	21d	9.9 mo	—	3	R 21 861 PFS proxy	2
Toremifene and Trastuzumab Variant #01	ER\|ERBB2	R 14 614	21d	19.2 mo	—	3	R 20 411 PFS proxy	1
Letrozole and Trastuzumab Variant #01	ER\|ERBB2	R 14 337	21d	12.4 mo	—	3	R 19 579 PFS proxy	2
Letrozole and Ribociclib Variant #01	ER	R 14 244	28d	25.3 mo	63.9 mo	65	R 565 168 PFS proxy	2
Tamoxifen and Trastuzumab Variant #01	ER\|ERBB2	R 14 161	21d	19.2 mo	—	3	R 19 052 PFS proxy	1
Exemestane and Trastuzumab Variant #01	ER\|ERBB2	R 14 085	21d	12.4 mo	—	3	R 18 825 PFS proxy	2
Anastrozole and Fulvestrant Variant #01	ER	R 11 043	28d	15.0 mo	47.7 mo	3	R 14 082 PFS proxy	2
Goserelin monotherapy Variant #01	ER	R 10 511	28d	—	—	~2	~R 18 395 indirect	—
Letrozole and Palbociclib Variant #01	ER	R 10 226	28d	21.5 mo	53.9 mo	2	R 20 453 PFS proxy	4
Anastrozole and Trastuzumab Variant #01	ER\|ERBB2	R 9 412	21d	5.6 mo	—	3	R 14 178 PFS proxy	3
Goserelin and Tamoxifen Variant #01	ER	R 8 293	28d	13.0 mo	48.0 mo	2	R 16 587 PFS proxy	2
Mitoxantrone and Vinorelbine (MV) Variant #01	—	R 5 320	21d	—	—	~2	~R 10 640 indirect	—
Gemcitabine and Paclitaxel Variant #01	TNBC	R 5 224	21d	6.5 mo	18.6 mo	6	R 31 344 PFS proxy	2
Carboplatin and Gemcitabine (GCb) Variant #01	TNBC	R 4 414	21d	5.5 mo	11.9 mo	2	R 8 829 PFS proxy	3
Cisplatin and Gemcitabine (GC) Variant #01	TNBC	R 3 933	21d	7.6 mo	—	6	R 23 595 PFS proxy	1
Capecitabine and Docetaxel (TX) Variant #01	TNBC	R 3 311	21d	8.4 mo	—	6	R 19 865 PFS proxy	1
Cisplatin and Docetaxel (DC) Variant #05	TNBC	R 3 185	21d	—	32.8 mo	3	R 9 556 PFS proxy	1
Docetaxel monotherapy Variant #02	TNBC	R 2 921	28d	8.2 mo	32.6 mo	10	R 29 215 PFS proxy	5
Fulvestrant monotherapy Variant #01	ER	R 2 721	28d	14.4 mo	44.8 mo	2	R 5 442 PFS proxy	6
STAMP-I Variant #01 Partial	—	R 2 292	—	—	—	~1	~R 2 292 indirect	—
Toremifene monotherapy Variant #01	ER	R 1 481	28d	—	—	~65	~R 96 275 indirect	—
FAC Variant #11	TNBC	R 1 076	21d	8.0 mo	17.3 mo	9	R 9 685 PFS proxy	3
Exemestane monotherapy Variant #01	ER	R 886	90d	9.9 mo	45.1 mo	2	R 1 771 PFS proxy	3
CAV Variant #06	—	R 865	21d	—	~7.6 mo	~6	~R 5 188 PFS proxy · indirect	1
VAP Variant #01	—	R 844	21d	—	—	~2	~R 1 688 indirect	—
Paclitaxel monotherapy Variant #02	TNBC	R 734	28d	6.9 mo	20.5 mo	7	R 5 141 PFS proxy	16
Letrozole monotherapy Variant #01	ER\|ERBB2	R 371	28d	14.5 mo	51.3 mo	65	R 24 107 PFS proxy	15
Letrozole monotherapy Variant #01	ER	R 371	28d	14.5 mo	51.3 mo	65	R 24 107 PFS proxy	15
Tamoxifen monotherapy Variant #01	ER	R 273	28d	6.8 mo	19.9 mo	65	R 17 763 PFS proxy	5
Anastrozole monotherapy Variant #01	ER	R 159	28d	13.8 mo	42.7 mo	65	R 10 342 PFS proxy	11
Anastrozole monotherapy Variant #01	ER\|ERBB2	R 159	28d	13.8 mo	42.7 mo	65	R 10 342 PFS proxy	11
Tamoxifen and Prednisolone Variant #01	ER	R 151	28d	—	—	~2	~R 303 indirect	—

49 of 49 regimens shown